Suven Life Sciences Limited SUVEN NSEPHARMA
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for treating gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -19.3% CAGR over 5 years.
- Earnings shrank at -44.6% CAGR over 5 years.
- RSI at 76 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SUVEN Suven Life Sciences Limited NSEPHARMA | 279.34 | - | ₹7,366.77 Cr | - | -46.55% | -78.80% | -19.30% | -44.55% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 1.47 Cr | 1.87 Cr | 91.92 L | 2.81 Cr | 1.52 Cr |
| Cost of Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | - | 1.47 Cr | 1.87 Cr | 91.92 L | 2.81 Cr | 1.52 Cr |
| Operating Expenses | - | 46.63 Cr | 53.98 Cr | 82.01 Cr | 107.50 Cr | 53.74 Cr |
| Operating Income | - | -45.17 Cr | -52.12 Cr | -81.09 Cr | -104.70 Cr | -52.22 Cr |
| EBITDA | - | -42.60 Cr | -50.15 Cr | -75.99 Cr | -100.58 Cr | -43.86 Cr |
| Interest Expense | - | 0 | 0 | 0 | 0 | 15.78 L |
| Pretax Income | - | -43.94 Cr | -51.52 Cr | -77.31 Cr | -101.92 Cr | -45.60 Cr |
| Tax Provision | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | - | -43.94 Cr | -51.52 Cr | -77.31 Cr | -101.92 Cr | -45.60 Cr |
| Diluted EPS | - | -2.02 | -2.36 | -3.48 | -4.55 | -2.02 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 13.54 Cr | 11.69 Cr | 6.66 Cr | 7.11 Cr |
| Cost of Revenue | - | 36.78 L | 71.79 L | 0 | 0 |
| Gross Profit | - | 13.17 Cr | 10.98 Cr | 6.66 Cr | 7.11 Cr |
| Operating Expenses | - | 145.09 Cr | 145.27 Cr | 178.25 Cr | 297.23 Cr |
| Operating Income | - | -131.92 Cr | -134.30 Cr | -171.60 Cr | -290.12 Cr |
| EBITDA | - | -111.44 Cr | -99.42 Cr | -154.88 Cr | -270.57 Cr |
| Interest Expense | - | 28.92 L | 15.84 L | 4.66 L | 15.78 L |
| Pretax Income | - | -118.27 Cr | -106.08 Cr | -160.75 Cr | -276.34 Cr |
| Tax Provision | - | 0 | -1.00 Cr | 0 | 0 |
| Net Income | - | -118.27 Cr | -105.08 Cr | -160.75 Cr | -276.34 Cr |
| Diluted EPS | - | -6.63 | -4.82 | -7.37 | -12.13 |
Compounded Sales Growth
| 5 Years: | -19.30% |
| 1 Year: | 3.60% |
Compounded Profit Growth
| 5 Years: | -44.55% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +20.72% |
| 6 Months: | +62.46% |
| 3 Months: | +87.53% |
| 1 Month: | +31.84% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 388.91 Cr | 284.90 Cr | 135.18 Cr | 624.21 Cr |
| Current Assets | - | 251.59 Cr | 256.67 Cr | 75.47 Cr | 546.71 Cr |
| Cash & Equivalents | - | 37.02 Cr | 14.93 Cr | 15.03 Cr | 8.28 Cr |
| Inventory | - | 0 | 70.84 L | 23.75 L | 10.20 L |
| Receivables | - | 80.74 L | 1.29 Cr | 1.34 Cr | 1.51 Cr |
| Total Liabilities | - | 13.59 Cr | 14.86 Cr | 25.20 Cr | 32.81 Cr |
| Current Liabilities | - | 11.13 Cr | 13.52 Cr | 23.49 Cr | 30.90 Cr |
| Long Term Debt | 0 | 0 | 0 | - | - |
| Total Debt | - | 1.61 Cr | 70.97 L | 0 | 16.69 Cr |
| Total Equity | - | 375.32 Cr | 270.04 Cr | 109.99 Cr | 591.40 Cr |
| Shares Outstanding | - | 21.81 Cr | 21.81 Cr | 21.81 Cr | 26.37 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -115.98 Cr | -82.62 Cr | -154.10 Cr | -301.79 Cr |
| Investing Cash Flow | - | -247.81 Cr | 61.59 Cr | 154.95 Cr | -462.11 Cr |
| Financing Cash Flow | - | 395.54 Cr | -1.05 Cr | -75.63 L | 757.15 Cr |
| Capital Expenditure | -19.77 Cr | -2.89 Cr | - | -37.28 Cr | -5.08 Cr |
| Free Cash Flow | - | -118.88 Cr | -82.62 Cr | -191.38 Cr | -306.87 Cr |
| Net Change in Cash | - | 31.75 Cr | -22.09 Cr | 9.31 L | -6.75 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 97.3% | 93.9% | 100.0% | 100.0% |
| Operating Margin % | - | -974.3% | -1,148.5% | -2,578.1% | -4,077.7% |
| Net Margin % | - | -873.5% | -898.6% | -2,415.1% | -3,884.1% |
| ROE % | - | -31.5% | -38.9% | -146.1% | -46.7% |
| ROCE % | - | -34.9% | -49.5% | -153.6% | -48.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SUVEN